Abstract
Carcinoma in situ represents high grade anaplasia of the bladder mucosa. Intravesical immunotherapy with bacillus Calmette-Guérin is the gold standard treatment for patients with carcinoma in situ. Patients with carcinoma in situ refractory to bacillus Calmette-Guérin are candidates for major surgery such as radical cystectomy. We identified the maximum tolerated dose and the recommended dose, and evaluated the safety profile of paclitaxel-hyaluronic acid bioconjugate given by intravesical instillation to patients with carcinoma in situ refractory to bacillus Calmette-Guérin.
| Original language | English |
|---|---|
| Pages (from-to) | 445-449 |
| Number of pages | 5 |
| Journal | THE JOURNAL OF UROLOGY |
| Volume | 185 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - 2011 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- 80 and over
- Adjuvants
- Administration
- Adolescent
- Adult
- Aged
- BCG Vaccine
- Biopsy
- Carcinoma in Situ
- Combination
- Cystoscopy
- Disease-Free Survival
- Dose-Response Relationship
- Drug
- Drug Administration Schedule
- Drug Resistance
- Drug Therapy
- Female
- Follow-Up Studies
- Humans
- Hyaluronic Acid
- Immunologic
- Intravesical
- Italy
- Male
- Maximum Tolerated Dose
- Middle Aged
- Needle
- Neoplasm
- Neoplasm Staging
- Paclitaxel
- Patient Selection
- Survival Analysis
- Treatment Outcome
- Urinary Bladder Neoplasms
- Young Adult
Fingerprint
Dive into the research topics of 'Paclitaxel-hyaluronic acid for intravesical therapy of bacillus Calmette-Guérin refractory carcinoma in situ of the bladder: results of a phase I study'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver